SOURCE: The Southern Nevada Chapter of The Leukemia & Lymphoma Society

February 14, 2007 11:40 ET

Leukemia & Lymphoma Society to Host Inaugural Dr. Emil Frei III Symposium

LLS Welcomes Pioneering Cancer Researcher to Nevada

LAS VEGAS, NV -- (MARKET WIRE) -- February 14, 2007 -- The Southern Nevada Chapter of The Leukemia & Lymphoma Society is hosting the first-ever Dr. Emil Frei III Symposium, to be held March 2nd and 3rd at the Four Seasons Hotel in Las Vegas. The symposium, a Certified Continuing Medical Education Program, will provide training for community-based medical oncologists, hematologists, fellows, primary care physicians and internists, based on the latest research regarding leukemias and lymphomas.

One of the world's leading oncologists and a pioneer in chemotherapy and medical research, Dr. Frei is now a Nevada resident and his symposium is expected to draw hundreds of medical professionals to the state. Nevada Governor Jim Gibbons has proclaimed March 3, 2007, as a day in honor of Dr. Emil Frei. Dr. Frei has recently received commendations or proclamations from:

--  Senator Harry Reid
--  Senator John Ensign
--  Congresswoman Shelley Berkley
--  Congressman Jon Porter
--  Congressman Dean Heller
--  Nevada Governor Jim Gibbons
--  State Senator Barbara Cegavske on behalf of the Nevada Legislature
--  Commissioner Rory Reid on behalf of Clark County
--  Councilwoman Lois Tarkanian on behalf of the City of Las Vegas
Dr. Frei will be honored for his lifetime of achievement in the field of medicine at the opening reception on Friday evening, at which several of these awards will be presented.

"We're thrilled to be hosting this event and welcoming Dr. Frei to Nevada," said Judith E. Mitchell, Executive Director of the LLS Southern Nevada Chapter. "We look forward to making it an annual event and contributing to Nevada's growing reputation as a center for medical continuing education."

For more information or to register for the symposium or the opening reception, please visit or contact Christina Goodman at (702) 436-4220, x102 or via email at

About Emil Frei III, MD

Dr. Emil Frei III is one of the world's leading oncologists, a pioneer of chemotherapy and a leader in medical research, clinical practice and education. His distinguished career includes 40 years in top leadership positions. He served as Chief of Medicine at National Cancer Institute, Associate Scientific Director at M. D. Anderson, and Director and Physician-in-Chief at the Dana-Farber Cancer Institute (formerly Sidney Farber Cancer Institute). He continues as Physician-in-Chief, Emeritus, at Dana-Farber.

He has been a major contributor to the successful application of chemotherapy, particularly the use of chemotherapeutic agents in combination for acute leukemia in children and in Hodgkin's disease and chemotherapy following surgical removal of the primary tumor in patients with the more common tumors including breast cancer and osteosarcoma. He produced major therapeutic advances in head and neck cancers. He has been particularly effective in applying the sciences of pharmacology, toxicology, clinical trial design and cytokinetics. Tens of thousands of patients have been cured by these treatments.

His contributions have been acknowledged by numerous awards including the Albert Lasker Award, the Kettering Prize from the General Motors Cancer Research Foundation and most recently the Inaugural Lifetime Achievement Award from the American Association for Cancer Research.

Dr. Frei's career in medicine began in 1948 after participating in the country's V-12 program of the Navy. He served in both WWII and the Korean War as a general physician including time on the battlefield. He then served at the National Institutes of Health (NIH) in the National Cancer Institute division as Chief of Medicine and was principal investigator in the leukemia research program.

He developed a reputation as a great institutional leader, particularly for his ability to secure funding and manage growing organizations. At M. D. Anderson in the late 1960's, he was instrumental in obtaining $1 million a year in operating funds from NIH for the development of cancer research programs. At the Farber Cancer Institute in the 1970's, he helped obtain a gift of $7 million from Charles A. Dana as seed money for partial construction of the institute's new permanent facility, and with the help of Massachusetts Senator Edward W. Brooke III, he was able to obtain the additional $10 million from NIH to complete construction.

He has been an industry leader, serving as past president of American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and Cancer and Leukemia Group B (CALGB) clinical research group. He has also served on the advisory or director boards of numerous companies and non-profit organizations, including Adherex Technologies, Angstrom, CaP Cure, Celator Pharmaceuticals, DIAD Research, Immunogen, Vion Pharmaceuticals, Aid for Cancer Research, Cancer Research Institute, Journal of Clinical Oncology and the New England Journal of Medicine.

Dr. Frei has been a leader in medical education, serving as Professor of Medicine at The University of Texas from 1965-1972 and at Harvard Medical School from 1972-1996. He holds the chair of the Richard and Susan Smith Distinguished Professor of Medicine at Harvard, established through a $3 million gift from philanthropists Michael Milken, Marvin Davis and Edward Bennett Williams to fund oncology research.

He has directed the education of over 300 oncologists, many of whom have become today's top leaders and researchers, and has lectured to thousands. Together with Dr. James Holland, Dr. Frei co-authored the first text in medical oncology, Cancer Medicine, the seventh edition of which is primary standard text of the field.

Dr. Frei has made Las Vegas his home with his family since 2004 and already has close ties to the community. He serves on the chapter board of the Southern Nevada Leukemia & Lymphoma Society. He also previously worked with current Nevada Cancer Institute Director Nicholas Vogelzang, M.D., on the CALGB clinical research group, of which Dr. Frei was Chairman at the time. Dr. Frei also chairs the Life Sciences Screening Committee for the Nevada Economic Development Advisory Board (NEDAB).

He lives next door to his stepson and daughter-in-law, Stephen and Kathryn Brock, and their four children. Kathryn Brock was born and raised in Las Vegas and her grandfather, Frank Scott, was one of the first economic development visionaries for the city. Stephen Brock is founder and CEO of Public Company Management Corporation (OTCBB: PUBC) and former President of the Nevada Business Journal.

Retired from full-time practice, Dr. Frei now lectures, writes and offers consulting services in areas including grant applications and reviews, clinical trials, industry collaboration and management advice.

For more information, visit

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 66 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $483 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact Information